Log in to save to my catalogue

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2566037781

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a randomized trial involving patients who had atrial fibrillation after TAVR, edoxaban was noninferior to vitamin K antagonists with respect to a composite outcome of death, MI, stroke, thromboembolism, valve thrombosis, or major bleeding but was associated with a higher incidence of major bleeding.

Alternative Titles

Full title

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2566037781

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2566037781

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2111016

How to access this item